ARDS is an acute inflammatory pulmonary process triggered by severe pulmonary and systemic insults to the alveolar-capillary membrane. This causes increased vascular permeability and the development of interstitial and alveolar protein-rich edema, leading to acute hypoxemic respiratory failure. Supportive treatment includes the use of lung-protective ventilatory strategies that decrease the work of breathing, can improve oxygenation, and minimize ventilator-induced lung injury. Despite substantial advances in supportive measures, there are no specific pharmacologic treatments for ARDS, and the overall hospital mortality rate remains about 40% in most series. The pathophysiology of ARDS involves interactions among multiple mechanisms, including immune cell infiltration, cytokine storm, alveolar-capillary barrier disruption, cell apoptosis, and the development of fibrosis. Here we review some new developments in the molecular basis of lung injury, with a focus on possible novel pharmacologic interventions aimed at improving the outcomes of patients with ARDS. Our focus is on platelet-endothelial cell adhesion molecule-1, which contributes to the maintenance and restoration of vascular integrity following barrier disruption. We also highlight the wingless-related integration site signaling pathway, which appears to be a central mechanism for lung healing as well as for fibrotic development.
overall hospital mortality rate remains about 40%. 2 Most patients with ARDS die as a result of multisystem organ failure and not due to lung failure (hypoxemia) per se. 3 The pathophysiology of ARDS is multifactorial and includes inflammation, barrier disruption, interstitial and airspace edema, cell injury, and cell death. 4 Diffuse alveolar damage is the pathologic hallmark of ARDS. As ARDS progresses through the exudative and proliferative phases, lung injury can increase, potentially leading to a fibrotic phase and worsening lung function. Lung-protective mechanical ventilation along with other adjunctive approaches (eg, prone position, judicious use of neuromuscular blocking agents) has been shown to decrease mortality. 4 Over the past two decades there has been intense-but to date, unsuccessful-research to develop pharmacologic therapies to treat ARDS.
In this short review, we discuss some new mechanistic insights at the molecular level that may have clinical implications for the development of novel therapies to modulate ventilator-associated damage and improve outcomes of patients with ARDS. We have chosen to focus on platelet-endothelial cell adhesion molecule-1 (PECAM1) since it is essential for maintaining endothelial cell junctions, and on wingless-related integration site (Wnt) signaling since it appears to be key to tissue remodeling and wound closure. We postulate that pharmacologic manipulation of these two molecules has great potential in maintaining the integrity, or repairing the alveolar-capillary membrane. Specifically, we will discuss the role of PECAM1 in the modulation of alveolar-capillary permeability and the production of inflammatory mediators; and the effects of Wnt signaling in the modification of cell death, fibrosis, and lung repair and regeneration.
Targeting the Integrity of Lung Endothelium in ARDS
In patients with ARDS there is injury to the alveolarcapillary membrane, [5] [6] [7] leading to increased permeability and pulmonary edema. 8, 9 Movement of plasma across the lung vascular bed results in the accumulation of protein-rich edema fluid in the pulmonary interstitium and the airspaces, even at normal pulmonary vascular pressure and without physical rupture of these structures.
The search for biomarkers of alveolar-capillary barrier damage has been a challenging journey. 7, 10 The alveolarcapillary barrier contains proteins that form tight and adherent junctions. CD31, also termed plateletendothelial cell adhesion molecule-1 (PECAM1), is a 130-kDa transmembrane protein that is a member of the immunoglobulin superfamily of adhesion molecules constitutively expressed and localized at endothelial cellcell junctions. 11 Synthesis of PECAM1 is tightly regulated within the vasculature. There is increasing evidence that PECAM1 contributes to the maintenance of vascular integrity in resting cells, as well as playing a role in restoration of vascular integrity following barrier disruption. 12 Blood flowing through the pulmonary vasculature during ventilatory-induced repetitive cyclic opening and closing of alveoli inflicts shear stress on pulmonary capillary endothelial cells (Fig 1) . The force generated is transmitted through cytoskeletal elements to sites of cell-cell adherence, where PECAM1 responds by activating downstream signaling pathways, including Src family kinase members, STAT-3 (signal transducer and activator of transcription-3), and integrins on the basal membrane of the cells. 13, 14 Extreme mechanical stress causes progressive changes in the shape and leads to loss of functional PECAM1.
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PECAM1 can be cleaved from endothelial cells by a number of mechanisms including shear stress, 16 resulting in a secreted, shed form of protein (sPECAM1) that is soluble and can be released into the circulation, exerting proinflammatory effects. [17] [18] [19] Inflammatory cells that have been activated can undergo shedding of the PECAM1 extracellular domain, which leads to loss of cell-cell adherence 17 and contributes to the increase in circulating sPECAM1. 18 Thus, circulating sPECAM1 levels may be measured as a biomarker to identify and monitor the development of ARDS and ventilatorinduced lung injury (VILI), and persistently high sPECAM1 levels may indicate ongoing injury. Using a clinically relevant experimental model of ARDS and VILI in animals with or without sepsis, Villar et al 20 showed that expression of PECAM1 in the lungs is modulated by mechanical ventilation. Their data strongly suggested that loss of PECAM1 contributes to increased barrier permeability with subsequent edema formation, leukocyte infiltration, and severe hypoxemia. Deficiency in the murine endothelial PECAM1 gene impedes repair of vascular integrity 21 and prolongs bleeding times. 22 Heterogeneous expression of PECAM1 has been reported in the pulmonary vessels of patients who died of ARDS 23 and in the lungs of children who received prolonged mechanical ventilation for bronchopulmonary dysplasia. 24 There is experimental evidence implicating mechanical ventilation in pulmonary and distal organ endothelial activation and inflammation. 25 Recovery from acute lung injury requires restoration of an intact endothelial barrier to ensure appropriate removal of pulmonary edema fluid. Since PECAM1 is essential for reestablishing endothelial integrity, it is an interesting target for the treatment of ARDS, sepsis, and VILI. In a mouse model of septic shock, Maas et al 26 transplanted
bone marrow cells expressing PECAM1 into mice that were deficient in PECAM1. Transplanted animals were resistant to endotoxic shock, and the integrity of the vascular barrier was better maintained after endotoxin challenge. Thus, there might be great potential for innovative therapies using genetically modified mesenchymal stromal cells expressing PECAM1 to reassemble the endothelial cell junctions in the treatment of ARDS and VILI. 27 We propose that upregulation of PECAM1 and/or reducing sPECAM1 through extracorporeal removal 28 or pharmacologic inhibition 29, 30 might be a novel therapeutic strategy in ARDS and VILI.
Attenuation of Lung Fibrosis to Enhance Lung Repair and Regeneration
As diffuse alveolar damage progresses in patients with ARDS, severe abnormal repair of alveolar epithelium and pulmonary capillary endothelium can develop into a fibrotic phase, resulting in poor lung function and death. 5 The fibroproliferative process observed in patients with ARDS is characterized by migration of Meanwhile, lung fibroblast proliferation and migration occur and are important for lung repair after injury. 32, 33 However, repetitive or/and sustained injury to the alveolar epithelium can lead to loss of ventilated alveolar units and a vigorous fibroblastic response, as a result of uncontrolled deposition of extracellular matrix (ECM) and collagen, leading to destruction of lung parenchymal architecture. 33, 34 Pulmonary fibrosis is a pathologic response in patients with ARDS, independent of the underlying inciting event that caused the initial lung injury. The tissue repair process includes coordinated cellular infiltration along with deposition of ECM and reepithelialization. In addition, the use of injurious ventilatory strategies plays a potential and additive role to further accelerate ECM remodeling, 33, 35 contributing to lung fibrosis and loss of lung function during ARDS. [36] [37] [38] Among other molecules and pathways, b-cateninmediated Wnt signaling appears to be an important mechanism in the context of pulmonary repair and fibrosis. endothelial dysfunction and increased microvascular permeability.
Wnt proteins attach to cell surface receptors of the Frizzled family, 41 as well as to other transmembrane proteins (eg, lipoprotein receptor-related protein), which leads to cytosolic accumulation of b-catenin. This then leads to translocation to the nucleus, where it participates in gene transcription and subsequent regulation of various genes, including Axin2 and Lgr5 (Fig 2) . Axin2, also known as axis inhibition protein-2 or conductin, is thought to play an important role in stabilizing b-catenin in the Wnt signaling pathway. 43 The leucine-rich G protein-coupled receptor-5 (LGR5) belongs to a glycoprotein hormone receptor superfamily, and it modulates signaling through the Wnt pathway after binding to its cognate ligand R-spondin. 44 Wnt signaling pathways, which are mediated by either paracrine or autocrine mechanisms, are regulated at multiple points. 45 Wnt signaling stimulates tissue remodeling through matrix metallopeptidases (MMPs) as well as other gene products such as cyclin D1 and vascular endothelial growth factor (VEGF). 40, 46, 47 The Wnt signaling pathways comprise a family of highly evolutionarily conserved secreted glycoproteins, which trigger many signaling pathways that control a number of processes including cell proliferation, differentiation, and migration. 40 Three Wnt signaling pathways have been characterized: the canonical Wnt pathway, the noncanonical planar cell polarity pathway, and the noncanonical Wnt/calcium pathway. The distinction of canonical and noncanonical Wnt signaling pathways is subject to debate, and a combined Wnt pathway has been suggested. 48 Expression of the nuclear transcriptional factor b-catenin can be decreased in AECII when there is destruction of alveolar walls and/or abnormal repair processes associated with deposition of ECM, such as in patients with COPD. 49 Reduced canonical Wnt/b-catenin signaling is linked to decreased lung repair as a result of a shift from canonical to noncanonical Wnt signaling. 50 Wnt-5A is a macrophage-derived molecule that is highly specific for macrophage activation, and is thought to play a role in pulmonary disorders. 51 Villar et al 37, 52 investigated whether Wnt/b-catenin signaling is activated early in experimental animals exposed to VILI and acute lung injury, as well as in patients with ARDS. They assessed lung protein levels of Wnt-5A and target genes (eg, MMP7, cyclin D1, VEGF) implicated in profibrotic alterations of injured tissues. 52 They used a clinically relevant experimental model of sepsis-induced ARDS, and found marked collagen deposition and increased Wnt-5A and MMP7 protein levels. Similar findings were observed in lung biopsies of patients who died early of sepsis-related ARDS. These results reinforced the concept that Wnt-5A and b-catenin pathway contribute to early repair of the lung. 40, 53 This is in accord 
Conclusions
In patients with ARDS there is increased alveolarcapillary permeability with protein-rich edema formation as a result of endothelial damage. PECAM1 is a transmembrane protein that connects adjacent endothelial cells and plays a role in the regulation of inflammation, leukocyte migration, and vascular responses during sepsis. We propose that upregulation of membrane PECAM1 may be a novel therapeutic strategy in ARDS and VILI.
Injury to alveolar epithelial cells activates pulmonary fibroblasts, inducing their transformation into matrixproducing myofibroblasts. The Wnt signaling pathways coordinate lung repair after injury, and hence the therapeutic manipulation of Wnt signaling in endogenous stem cells may be exploited for tissue renewal and regeneration during early ARDS.
